Jan 31, 2022
Immutep to Present at February Investor Conferences
Jan 24, 2022
Immutep Quarterly Activities Report
Dec 15, 2021
Immutep Advances IMP761 Manufacturing
Dec 01, 2021
Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003
Nov 19, 2021
Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha
